Alpha Tau Medical (NASDAQ:DRTS) PT Lowered to $8.00 at Piper Sandler

Alpha Tau Medical (NASDAQ:DRTSGet Free Report) had its price objective cut by research analysts at Piper Sandler from $12.00 to $8.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler’s price target would suggest a potential upside of 175.86% from the stock’s current price.

Other analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Alpha Tau Medical in a research report on Wednesday, September 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $23.00 price target on shares of Alpha Tau Medical in a research report on Tuesday, August 29th.

View Our Latest Analysis on Alpha Tau Medical

Alpha Tau Medical Stock Down 1.0 %

Shares of NASDAQ:DRTS traded down $0.03 during trading on Friday, hitting $2.90. The stock had a trading volume of 10,159 shares, compared to its average volume of 56,000. The company has a market capitalization of $201.17 million, a PE ratio of -9.06 and a beta of 0.93. The firm’s fifty day moving average is $3.39 and its 200 day moving average is $3.67. Alpha Tau Medical has a 12 month low of $2.75 and a 12 month high of $5.95.

Alpha Tau Medical (NASDAQ:DRTSGet Free Report) last posted its quarterly earnings results on Monday, August 28th. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). Equities research analysts expect that Alpha Tau Medical will post -0.49 EPS for the current fiscal year.

Institutional Trading of Alpha Tau Medical

A number of large investors have recently made changes to their positions in the stock. Penserra Capital Management LLC bought a new stake in Alpha Tau Medical in the 1st quarter worth approximately $40,000. Activest Wealth Management bought a new stake in shares of Alpha Tau Medical in the second quarter worth $28,000. Tower Research Capital LLC TRC purchased a new stake in Alpha Tau Medical during the third quarter valued at $37,000. Geode Capital Management LLC lifted its holdings in Alpha Tau Medical by 31.4% in the first quarter. Geode Capital Management LLC now owns 26,606 shares of the company’s stock valued at $76,000 after acquiring an additional 6,364 shares during the period. Finally, Morgan Stanley boosted its position in Alpha Tau Medical by 60.6% in the fourth quarter. Morgan Stanley now owns 18,603 shares of the company’s stock worth $59,000 after purchasing an additional 7,020 shares during the last quarter. 1.47% of the stock is currently owned by institutional investors.

Alpha Tau Medical Company Profile

(Get Free Report)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

See Also

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with's FREE daily email newsletter.